Pepinemab
- Generic Name
- Pepinemab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 2097151-87-4
- Unique Ingredient Identifier
- BPZ4A29SYE
- Background
Pepinemab is under investigation in clinical trial NCT03769155 (VX15/2503 With or Without Ipilimumab and/or Nivolumab in Patients With Resectable Stage IIIB-D Melanoma).
- Associated Conditions
- -
- Associated Therapies
- -
Adoptive T Cell Therapy Following HER2-Pulsed Dendritic Cell Vaccine & Pepinemab /Trastuzumab in Patients w/ Metastatic HER2+ Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-05-18
- Last Posted Date
- 2024-12-06
- Target Recruit Count
- 28
- Registration Number
- NCT05378464
- Locations
- ๐บ๐ธ
Moffitt Cancer Center, Tampa, Florida, United States
SEMA4D Blockade Safety and Brain Metabolic Activity in Alzheimer's Disease (AD)
- First Posted Date
- 2020-05-08
- Last Posted Date
- 2024-08-22
- Lead Sponsor
- Vaccinex Inc.
- Target Recruit Count
- 50
- Registration Number
- NCT04381468
- Locations
- ๐บ๐ธ
University of Rochester Medical Center, Rochester, New York, United States
๐บ๐ธIndiana University School of Medicine, Indianapolis, Indiana, United States
๐บ๐ธJEM Research Institute, Lake Worth, Florida, United States
A Study in Subjects With Late Prodromal & Early Manifest HD to Assess the Safety, Tolerability, pk, and Efficacy of Pepi
- First Posted Date
- 2015-06-25
- Last Posted Date
- 2022-05-02
- Lead Sponsor
- Vaccinex Inc.
- Target Recruit Count
- 301
- Registration Number
- NCT02481674
- Locations
- ๐บ๐ธ
University of Vermont, Burlington, Vermont, United States
๐บ๐ธUniversity of California, San Diego, La Jolla, California, United States
๐บ๐ธJohns Hopkins University, Baltimore, Maryland, United States
Evaluation of Safety, Tolerability, and PK of VX15/2503 In Patients With MS
- First Posted Date
- 2013-01-10
- Last Posted Date
- 2015-02-06
- Lead Sponsor
- Vaccinex Inc.
- Target Recruit Count
- 50
- Registration Number
- NCT01764737
- Locations
- ๐บ๐ธ
Wayne State University - University Health Center, Detroit, Michigan, United States
๐บ๐ธUniversity of Colorado Hospital, Aschutz Inpatient Pavilion, Aurora, Colorado, United States
๐บ๐ธNorth Central Neurology Associates, PC, Cullman, Alabama, United States
Evaluation of Safety, Tolerability, PK & PD of Intravenous VX15/2503 in Patients With Advanced Solid Tumors
- First Posted Date
- 2011-03-11
- Last Posted Date
- 2014-08-13
- Lead Sponsor
- Vaccinex Inc.
- Target Recruit Count
- 42
- Registration Number
- NCT01313065
- Locations
- ๐บ๐ธ
South Texas Accelerated Research Therapeutics, LLC, San Antonio, Texas, United States
๐บ๐ธVirginia G. Piper Cancer Center at Scottsdale Healthcare, Scottsdale, Arizona, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.